They say the road to hell is paved with good intentions.
They say the road to hell is paved with good intentions. The row in the UK over NICE’s call to doctors to increase the use of statins looked to be good example of this handy aphorism. That was until things took a potentially darker turn.
NICE has said that any healthy person with a 10 per cent risk of suffering a heart attack or stroke within the next decade should be taking a statin. Currently those with a 20 per cent risk are prescribed the drug.
With cardiovascular disease killing one in three people, NICE’s proposals “are intended to prevent many lives being destroyed,” said Prof Mark Baker, director of NICE’s centre for clinical practice.
This week however a group of eight signatories, including the President of the Royal College of Physicians and a past chair of the Royal College of GPs, published an open letter to NICE and the UK government’s Health Secretary, Jeremy Hunt, warning that the statin guidance will “medicalize” up to five million health people.
The benefits of statins do not outweigh the side-effects, the signatories believe, warning that patients will be unnecessarily exposed to diabetes, memory loss, and muscle pain, among other conditions. What’s more, they went on, NICE’s research reveals an “over dependence” on industry data. “Extensive evidence shows that industry-funded trials systematically produce more favorable outcomes than non-industry sponsored ones.”
Today the Daily Mail and others took this industry-bias bone and ran with it. Half of the 12-strong expert panel advising NICE on the statins, the Mail declared, “have financial ties to drugs firms making the pills”.
The panel’s chairman, Dr Anthony Wierzbicki, claims the Mail, “has been given funds likely to total tens of thousands of pounds from five drugs firms which make statins or similar cholesterol-lowering pills”. Dr Rajai Ahmad, Cardiologist at Sandwell and West Birmingham Hospitals, “has been paid by Bayer, Boehringer Ingelheim and MSD to give speeches or offer advice”. Even the panel’s senior nurse, Emma McGowan, was reportedly financially supported by AstraZeneca for the first year of her job at Coventry and Warwickshire Hospital, as well as being ”paid by Merck, which also makes statins, to give speeches to nurses.” And so on.
NICE is used to facing backlash over its recommendations and refusals. It might have been amusing to see it face similar criticism over urging the NHS to spend more on a particular treatment. But the conflict-of-interest accusations might prove the undoing of its good intentions in this case.
Young & Partners Pharmaceutical Executive Summit 2024: Brave New World – Where Are We Heading?
October 23rd 2024Peter Marks, director, Center for Biologics Evaluation and Research, FDA, presented the keynote presentation on the future of gene therapy as part of the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Unlocking value and cost savings in patient services with technology and talent
October 2nd 2024Traci Miller, Director, Sonexus™ Access and Patient Support, Cardinal Health, discusses the current digital trends in the patient services industry and how the optimal balance of technology and talent can transform manufacturer-sponsored patient support programs. Hear how Cardinal Health combines best-in-class program and pharmacy operations with smart digital tools to ensure product and patient success and reduce operational costs.